TargeGen Affiliates Scheduled for Oral Presentation of Interim Clinical Trial Data at 2008 ASH Meeting in San Francisco for TG101348, a Potent, Selective, Oral JAK2 Inhibitor in Myeloproliferative Disease Patients

SAN DIEGO, Dec. 1 TargeGen has announced that an oralpresentation of preliminary results from a multi-center, US-based clinicaltrial of TG101348 in myeloproliferative disease patients has been scheduled atthe 2008 American Society of Hematology (ASH) Meeting.

About TargeGen, Inc.

TargeGen, Inc. is a privately held vascular biology-focusedbiopharmaceutical company based in San Diego, CA. TargeGen primarily developssmall molecule kinase inhibitors that target vascular leakage (edema),vascular proliferation (angiogenesis) and inflammation. Edema, angiogenesisand inflammation are involved in the pathology of many major human diseases.TargeGen initiated operations in 2002 and has raised capital from top tierventure capital sources. Current investors include VantagePoint VenturePartners, Forward Ventures, Enterprise Partners, Chicago Growth Partners, BBBIOTECH VENTURES, Innovis Investments, H&Q Capital Management, PappasVentures, CTI Life Sciences and other investors.

(Logo: http://www.newscom.com/cgi-bin/prnh/20030430/TARGEGENLOGO)Details of the presentation are as follows: Title: A Phase I Study of TG101348, an Orally Bioavailable JAK2-Selective Inhibitor, in Patients with Myelofibrosis Presenter: Dr. Animesh Pardanani, Mayo Clinic Session Name: Myeloproliferative Disorders-Experimental Therapeutics Session Date: Sunday, December 7, 2008 Presentation Time: 4:30 PM Room: Moscone Center SOUTH, Rooms 304-306-308 Directions: Howard Street entrance, turn left, up 2 flights of stairs to Esplanade level

SOURCE TargeGen, Inc.

Latest Press Release on General News

World IBS Day - April 19th: Raising Awareness for Everyone with IBS

Debunking myths about Irritable Bowel Syndrome TORONTO , April 18, 2024 /PRNewswire/ -- IBS is a chronic gastrointestinal disorder with symptoms like abdominal pain, bloating,...

Important step taken on the Canada Disability Benefit in Budget 2024, but funding falls short

More work must be done to lift Canadians with disabilities out of poverty TORONTO , April 17, 2024 /CNW/ - The federal government has taken an important step on the Canada Di...

Hydrinity Accelerated Skin Science Introduces MicroFusion Technology and Expands Facial Skincare Line with PRELUDE Facial Treatment Cleanser and HYDRI-C Vitamin C Moisturizer

The Next Generation Technology with the Power to Transform Skin MONROE, La. , April 15, 2024 /PRNewswire/ -- Hydrinity Accelerated Skin Science announced today the launch of t...

A 2017 Hyundai Elantra and 760,000 kilometres of life-saving blood donation deliveries

Mr. Tim German's 2017 Hyundai Elantra a.k.a. "Dark Angel," was bought new from Steele Hyundai Halifax and now has more than 760,000 kilometres on the odometer. With his Elantra, Mr....

Philips Respironics Reaches Agreement with US Government on a Consent Decree Creating a Clear Path Forward

April 10, 2024 Philips confirms that further to communicating the main terms of the Philips Respironics consent decree on January 29, 2024, Philips’ subsidiaries Philips Holding USA ...